Paul Tudor Jones’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Paul Tudor Jones’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,849	Closed	-$81.5K	–	4388
2026 Q1	$81.5K	Hold	34,849	–	–	﹤0.01%	3470
2025 Q4	$47K	Hold	34,849	–	–	﹤0.01%	3398
2025 Q3	$52.6K	Hold	34,849	–	–	﹤0.01%	3279
2025 Q2	$40.4K	Hold	34,849	–	–	﹤0.01%	3168
2025 Q1	$55.4K	Sell	34,849 -320	-0.9%	-$690	﹤0.01%	2955
2024 Q4	$107K	Sell	35,169 -540	-2%	-$1.77K	﹤0.01%	2904
2024 Q3	$131K	Buy	+35,709	New	+$130K	﹤0.01%	2573
2024 Q2	–	Sell	-35,303	Closed	-$556K	–	2876
2024 Q1	$556K	Buy	+35,303	New	+$486K	﹤0.01%	1608
2023 Q4	–	Sell	-35,225	Closed	-$707K	–	2981
2023 Q3	$707K	Buy	+35,225	New	+$894K	0.01%	1498
2023 Q1	–	Sell	-20,054	Closed	-$404K	–	3032
2022 Q4	$404K	Buy	+20,054	New	+$431K	0.01%	1726
2022 Q2	–	Sell	-15,531	Closed	-$717K	–	2585
2022 Q1	$717K	Sell	15,531 -7,610	-33%	-$411K	0.02%	1066
2021 Q4	$1.95M	Buy	+23,141	New	+$1.79M	0.03%	643
2020 Q4	–	Sell	-37,628	Closed	-$1.23M	–	1674
2020 Q3	$1.23M	Buy	+37,628	New	+$1.32M	0.05%	497

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Paul Tudor Jones's ZNTL Position: Q2 2026 in Review

Paul Tudor Jones sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 34,849 shares — an estimated $81.5K sold.

Paul Tudor Jones first reported a position in ZNTL in Q3 2020 and held it in 13 quarters. The position peaked at $1.95M in Q4 2021. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Paul Tudor Jones reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 34,849 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $81.5K.
Paul Tudor Jones first reported a position in Zentalis Pharmaceuticals in Q3 2020 and held it in 13 quarters.
Paul Tudor Jones's Zentalis Pharmaceuticals position peaked at $1.95M in Q4 2021.
113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.